Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).
Also, 24/7 Wall St. has taken a look at 10 other major biotech events coming in the first month of 2018. These events could influence a move of over 10% in the stock, whether it's to the upside or downside.
Atara intends to initiate these studies imminently. Tabelecleucel is Atara’s off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic and solid tumors.
The Phase 3 studies are expected to open for enrollment in the United States imminently and will later expand to include sites in the European Union, Canada and Australia.
Top 10 Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)
Advisors' Opinion:- [By Jon C. Ogg]
In September of 2016, Amgen Inc. (NASDAQ: AMGN) announced that the FDA had approved its Amjevita as a biosimilar to Humira for multiple inflammatory diseases that included RA and several other related inflammatory diseases.
- [By Keith Speights]
Gilead Sciences (NASDAQ:GILD), Amgen (NASDAQ:AMGN), and Johnson & Johnson (NYSE:JNJ) rank as the three top biopharmaceutical companies when it comes to cash stockpiles. Here's what these drugmakers are most likely to do with all that money -- and whether or not you should consider investing some of your hard-earned cash to buy their stocks.
- [By Todd Campbell]
Amgen (NASDAQ:AMGN) may not be as exciting a stock to own as clinical-stage upstarts, but shares in this biotech Goliath have been mounting a rally lately that should make every investor take notice. So far in 2018, Amgen's rewarded investors with an 18% return.
- [By ]
This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV) , Amgen (AMGN) , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN) and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days," according to Real Money Pro columnist Bret Jensen.
Top 10 Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By Steve Symington]
But several individual stocks lagged the broader market. Read on to see why Cerner (NASDAQ:CERN), Biogen (NASDAQ:BIIB), and Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) slumped today.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 4.29 million shares from the previous 4.73 million. The stock recently traded at $344.10, within a 52-week range of $249.17 to $370.57.
- [By Shannon Jones]
In this week's episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte's Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis' (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB) might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.
Top 10 Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Jim Crumly]
Commercial success for Tegsedi is not a done deal even if it's approved worldwide; Alnylam Pharmaceuticals' (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam's clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.
- [By Cory Renauer]
If approved, Tegsedi will run directly into competition with Alnylam's (NASDAQ:ALNY) recently approved treatment for the limited population of ATTR patients, Onpattro. Inotersen and Onpattro haven't been tested in a head-to-head study, but most analysts expect Alnylam's drug to gain a much larger share of the limited space than Akcea's.
- [By Brian Orelli]
Following the Food and Drug Administration (FDA) approval of Onpattro, Alnylam Pharmaceuticals' (NASDAQ:ALNY) first drug to treat hereditary transthyretin-mediated amyloidosis (hATTR), the biotech held a conference call to go over the plan for launch. Here are three things management wants investors to know:
- [By Keith Speights]
Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.
Top 10 Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Stephan Byrd]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Cory Renauer]
What's behind these dramatic gains? Read on to find out.
Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billionData source: YCharts.
- [By Money Morning Staff Reports]
But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we'll show you a small-cap stock with great profit potential in its future…
Penny Stock Current Share Price Law Month's Gain Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85% Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40% Vivis Inc. (Nasdaq: VVUS) $0.77 150.41% Adomani Inc. (Nasdaq: ADOM) $1.49 137.68% NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88% Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06% Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12% ArQule Inc. (Nasdaq: ARQL) $4.88 90.74% LiqTech International Inc. (NYSE: LIQT) $0.66 85.60% Transenterix Inc. (NYSE: TRXC) $3.46 77.84%While last month's gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.
No comments:
Post a Comment